Despite numerous clinical trials and pre-clinical developments, the treatment of glioblastoma
(GB) remains a challenge. The current survival rate of GB averages one year, even with an …

PET imaging using radiolabeled amino acids in addition to MRI has become a valuable
diagnostic tool in the clinical management of patients with brain tumors. This review …

The number of positron-emission tomography (PET) tracers used to evaluate patients with
brain tumors has increased substantially over the last years. For the management of patients …

A series of novel 2-benzylthio-4-chloro-5-(5-substituted 1, 3, 4-oxadiazol-2-yl)
benzenesulfonamides (4–27) have been synthesized as potential anticancer agents. MTT …

Simple Summary Sulfonate derivatives have limited application in pharmacology. Only few
examples of small-molecule alkylating agents used as DNA poisons are known. This is the …

Gliomas are the most common primary brain tumors in adults. A diffuse infiltrative growth
pattern and high resistance to therapy make them largely incurable, but there are significant …

Abstract Background We evaluated O-(2-[18F] fluoroethyl)-l-tyrosine (FET) PET and MRI for
early response assessment in recurrent glioma patients treated with lomustine-based …

Mutations in the isocitrate dehydrogenase gene 1 (IDH1) are common in gliomas. Studies
suggest that IDH1 mutations are early events in glioma formation and are important drivers …

Mutations in the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) are commonly found
in gliomas. AGI-5198, a potent and selective inhibitor of the mutant IDH1 enzyme, was …

Mutations of isocitrate dehydrogenase 1 (IDH1) are key biomarkers for glioma classification,
but current methods for detection of mutated IDH1 (mIDH1) require invasive tissue sampling …